In the early 2000s a group of scientists at Stanford University, California, revived a grisly procedure used in the 1950s known as parabiosis. They paired living mice, young with old, peeled back their skin and stitched together their sides so the two animals shared the same blood circulatory system. A month later, they found signs of rejuvenation in the muscles and livers of the old mice. The findings, published in 2005, turned the minds of scientists, entrepreneurs and the public to the potential of young blood to rejuvenate ageing people. By 2016, enough interest had grown to prompt a US-based startup called Ambrosia to start offering pricey infusions of young plasma – the cell-free component of blood. The procedure came under fire from the US Food and Drug Administration early last year both for its lack of proven clinical benefit and for potential safety issues; Ambrosia closed, though it has recently reopened.

Artificial Intelligence (AI) in healthcare is expected to revolutionise the sector. Expectations are high and since 2015 the number of medical algorithms approved by the FDA has grown exponentially. We can see it in this interesting infographic designed by Dr. Bertalan Mesko (@Berci), known as the Medical Futurist, which shows that in 2014 only AliveCor's algorithm for the detection of atrial fibrillation was approved, and then in recent years dozens of algorithms have burst onto the scene with the go-ahead of the FDA, among them, products from Apple and Verily. However, the hype in which AI has been involved has left us some disappointments. But in recent years, a great number of startups and healthcare organisations are getting tangible results in AI applied to different medical fields.

What exactly is biotechnology, and how could it change our approach to human health? As the age of big data transforms the potential of this emerging field, members of the World Economic Forum's Global Future Council on Biotechnology tell you everything you need to know. What if your doctor could predict your heart attack before you had it – and prevent it? Or what if we could cure a child's cancer by exploiting the bacteria in their gut? These types of biotechnology solutions aimed at improving human health are already being explored. As more and more data (so called "big data") is available across disparate domains such as electronic health records, genomics, metabolomics, and even life-style information, further insights and opportunities for biotechnology will become apparent. However, to achieve the maximal potential both technical and ethical issues will need to be addressed. As we look to the future, let's first revisit previous examples of where combining data with scientific understanding has led to new health solutions. Biotechnology is a rapidly changing field that continues to transform both in scope and impact. Karl Ereky first coined the term biotechnology in 1919.

Several industries are seeing the impact of robotics -- and medicine is no exception. While the progress of these applications has been slow compared to other industries, the impact could be huge: robotics in medicine can help to reduce human error, improve recovery time, and reduce hospital stays, ultimately enhancing patients' quality of life. The first medical robotic application appeared in 1985, when an early robotic surgical arm assisted in a neurosurgical biopsy surgery. Fifteen years later, the first fully FDA-approved system (known as the da Vinci surgery system) for laparoscopic surgery emerged, giving surgeons the ability to control surgical instruments indirectly via a console. Today, companies are leveraging advances in the tech to develop new robotic applications to explore the future of medicine -- including those related to bionics, disease discovery, and rehabilitation.

This accessibility tech promises to make it safer than ever to live independently (Photo: Reviewed.com) Purchases you make through our links may earn us a commission. Technology may be entertaining, but at its essence, its primary function is to make our lives easier. When we want to find answers to our questions, communicate with friends, secure our homes, or hundreds of other scenarios, we turn to technology. At CES 2020, technology took on another role: helping us care for ourselves and loved ones.

Artificial intelligence is already ubiquitous, and is increasingly being used to autonomously make ever more consequential decisions. However, there has been relatively little research into the consequences for equity of the use of narrow AI and automated decision systems in medicine and public health. A narrative review using a hermeneutic approach was undertaken to explore current and future uses of AI in medicine and public health, issues that have emerged, and longer-term implications for population health. Accounts in the literature reveal a tremendous expectation on AI to transform medical and public health practices, especially regarding precision medicine and precision public health. Automated decisions being made about disease detection, diagnosis, treatment, and health funding allocation have significant consequences for individual and population health and wellbeing. Meanwhile, it is evident that issues of bias, incontestability, and erosion of privacy have emerged in sensitive domains where narrow AI and automated decision systems are in common use. As the use of automated decision systems expands, it is probable that these same issues will manifest widely in medicine and public health applications. Bias, incontestability, and erosion of privacy are mechanisms by which existing social, economic and health disparities are perpetuated and amplified. The implication is that there is a significant risk that use of automated decision systems in health will exacerbate existing population health inequities. The industrial scale and rapidity with which automated decision systems can be applied to whole populations heightens the risk to population health equity. There is a need therefore to design and implement automated decision systems with care, monitor their impact over time, and develop capacities to respond to issues as they emerge.

Technology may be entertaining, but at its essence, its primary function is to make our lives easier. When we want to find answers to our questions, communicate with friends, secure our homes, or hundreds of other scenarios, we turn to technology. At CES 2020, technology took on another role: helping us care for ourselves and loved ones. In an effort to make living with disabilities and aging in place as safe and independent as possible, companies are promising smart technology that allows you to better assess you or a loved one's health and environment. Linksys Wellness Pods use WiFi to track motion and respiratory changes.

Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. Updates are provided on a monthly basis. Sign-Up for our newsletter and never miss out on the latest news and updates. As 2019 came to an end, Veritas Genetics struggled to get funding due to concerns it had previously taken money from China. It was forced to cease US operations and is in talks with potential buyers. The GenomeAsia 100K Project announced its pilot phase with hopes to tackle the underrepresentation of non-Europeans in human genetic studies and enable genetic discoveries across Asia. Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyers Veritas Genetics ceases US operations but will continue Veritas Europe and Latin America. It had trouble raising funding due to previous China investments and is looking to be acquired. Illumina loses DNA sequencing patents The European Patent ...

A startup from the University of California-Los Angeles (UCLA) is developing an AI-based tool that analyzes spine images to inform patients whether or not they need surgery. Based on research conducted by UCLA neurosurgeon Dr. Luke Macyszyn, the startup Theseus AI aims to address the costly medical problem of unnecessary spine surgeries. Studies show that between 20 and 40 percent of spine surgeries fail to relieve pain, and there are more than 250,000 performed each year. "This is somewhat personal for me in that my own father had spine surgery twice," says Sam Elhag, CEO of Theseus AI. "To this date, it's uncertain as to whether or not it all made sense." Elhag launched Theseus to make the interpretation of spine MRIs less subjective.

Aidoc, the leading provider of AI solutions for radiologists, today announced that the US Food and Drug Administration (FDA) has cleared its AI solution for flagging Large-Vessel Occlusion (LVO) in head CTA scans, marking Aidoc's fourth FDA-cleared AI package. Combined with Aidoc's previously-cleared AI module for flagging and prioritizing intracranial hemorrhage, together they provide a comprehensive AI package for the identification and triage of both ischemic and hemorrhagic stroke in CTs, speeding time to treatment when every minute counts. "Stroke is the ultimate time-critical condition," said Dr. Marcel Maya, Co-chair Department of Imaging, Cedars-Sinai Medical Center. "The faster we can identify, diagnose and treat it, the better the outcome for patients. Aidoc's comprehensive stroke package flags both large vessel occlusion and hemorrhages inside our existing workflows, ensuring we can diagnose stroke faster and decide on the best course of treatment. We're already seeing how this has a positive impact on department efficiency and patient length of stay."